Important Safety Information : Tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Moreover, GLP-1 and GLP-1 receptor agonists increase satiety, leading to a reduction in weight (95)
Medicare will begin covering GLP-1 medications for obesity through the Medicare GLP-1 Bridge program starting July 1, 2026, offering eligible beneficiaries access for $50 per month
For some people, nutrition, exercise, sleep and stress management may provide meaningful improvements on their own
Body fat percentage continues to drop because muscle gain offsets fat loss on the scale
At times, frustration or even a loss of quality of life from the reduced pleasure obtained from food (or other aspects of life) may result in changes in affect and potentially medication discontinuation [148]